

Stem cell transplantation in human testis for the treatment of male infertility

Submission date
05/01/2009

Recruitment status
No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date
27/02/2009

Overall study status
Completed

☐ Statistical analysis plan

☐ Results

Last Edited
27/02/2009

Condition category
Urological and Genital Diseases

☐ Individual participant data

☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Zaid Kilani

Contact details

The Farah Hospital
May Ziadeh Street
P.O. Box 5323
Jabal
4th circle
Amman
Jordan
11183
+962 6 460 3555
farah1@go.com.jo

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Bone marrow stem cell transplantation in human testis for men with severe oligospermia or azospermia: a pilot study

Study objectives

Testes have two main functions in mammals: to produce androgens and spermatogenesis which occurs in the seminiferous tubules. Spermatogonial stem cells are undifferentiated cells defined by their ability to both self-renew and differentiate into mature spermatozoa. Bone marrow stem cells (BMS cells) have been shown to be able to transdifferentiate to male germ cell-like cells. In male mice, a recent study has demonstrated that bone marrow stem cells are able to differentiate into primordial germ cells and spermatogonia both in vitro and in vivo.

In a more recent study, adult bone marrow cells injected into seminiferous tubules or interstitial spaces were not only able to differentiate into germ cells (spermatogonia and spermatocytes) but as well as Sertoli and Leydig cells. This finding may be of clinical relevance to unique treatment of male infertility. The ability to derive male germ cells from BMS cells opens the possibilities for use of these cells in reproductive medicine mainly male infertility. In order to encourage BMS cells to differentiate into germ cells, the isolated cells should be cultured in a medium very similar to that found in the testes. Thus, Obtaining BMS cells from the infertile man and injecting it - after preparation - into the seminiferous tubules or around it may stimulate its differentiation into germ cells.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The Farah Hospital Ethical Committee, approved on 13/12/2008 (ref: 1).

Study design

Prospective randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Male infertility and spermatogenesis

Interventions

Forty men with severe oligospermia and 20 men with azospermia will be recruited (total: 60 participants).

Participants will be randomised to have BMS cells transplantation or no therapy. In the oligospermia group, 20 cases will receive BMS cells and in the azospermia group, only 10 will receive it. Randomisation ratio will be 1:1.

For safety of participants, BMS cells will be injected in one testis only and the other testis will be spared.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

1. Laboratory safety: White Cell Count (WCC) and platelet count, assessed once per month for three months
2. In azospermia group: Histopathology of evidence of differentiation. Testicular biopsy will be obtained after three months of injection.
3. In oligospermia group: Significant increase in number of sperms on three successive semen samples, assessed after 1, 2 and 3 months of injection

All primary outcome measures will be followed up for 180 days.

Secondary outcome measures

1. Sperm activity and ability to fertilise oocyte, assessed each time sperm is obtained throughout the study
2. Pregnancy rate within one year of injection
3. Miscarriage rate within one year of injection
4. Long term follow-up for any adverse effect, assessed for one year from injection

All secondary outcome measures will be followed-up for one year.

Overall study start date

15/01/2009

Completion date

01/06/2010

Eligibility**Key inclusion criteria**

1. Men with idiopathic severe oligospermia defined as less than one million sperm per ml, or men with azospermia

2. Men between 20-50 years old
3. Normal serum levels of gonadotropines, testosterone and prolactine
4. Absence of infectious genital disease and anatomical abnormalities of the genital tract
5. Absence of smoking, drug addiction or alcohol consumption

Participant type(s)

Patient

Age group

Adult

Sex

Male

Target number of participants

60

Key exclusion criteria

1. Men with previous surgery in testis
2. Those with major medical problem such as malignancy, hepatitis, etc.

Date of first enrolment

15/01/2009

Date of final enrolment

01/06/2010

Locations**Countries of recruitment**

Jordan

Study participating centre

The Farah Hospital

Amman

Jordan

11183

Sponsor information**Organisation**

The Farah Hospital (Jordan)

Sponsor details

May Ziadeh Street
P.O. Box 5323
Jabal
4th circle
Amman
Jordan
11183
+962 6 460 3555
farah1@go.com.jo

Sponsor type

Hospital/treatment centre

Website

<http://www.farah-hospital.org/>

ROR

<https://ror.org/02qnzpb65>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

The Farah Hospital (Jordan)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration